First Allied Advisory Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

First Allied Advisory Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,854	Closed	-$229K	–	1183
2020 Q2	$229K	Buy	+1,854	New	+$184K	0.01%	937
2019 Q3	–	Sell	-3,087	Closed	-$264K	–	1640
2019 Q2	$264K	Sell	3,087 -97	-3%	-$8.3K	0.01%	949
2019 Q1	$281K	Buy	+3,184	New	+$295K	0.01%	899
2018 Q1	–	Sell	-2,533	Closed	-$224K	–	1191
2017 Q4	$224K	Buy	2,533 +100	+4%	+$8.7K	0.01%	995
2017 Q3	$229K	Buy	2,433 +18	+0.7%	+$1.59K	0.01%	941
2017 Q2	$225K	Hold	2,415	–	–	0.01%	973
2017 Q1	$212K	Sell	2,415 -102	-4%	-$9.07K	0.01%	963
2016 Q4	$209K	Sell	2,517 -390	-13%	-$33.5K	0.01%	970
2016 Q3	$269K	Buy	+2,907	New	+$274K	0.01%	793

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Allied Advisory Services's BMRN Position: Q3 2020 in Review

First Allied Advisory Services sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 1,854 shares — an estimated $229K sold.

First Allied Advisory Services first reported a position in BMRN in Q3 2016 and held it in 9 quarters. The position peaked at $281K in Q1 2019. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

First Allied Advisory Services reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
First Allied Advisory Services sold 1,854 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $229K.
First Allied Advisory Services first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 9 quarters.
First Allied Advisory Services's BioMarin Pharmaceuticals position peaked at $281K in Q1 2019.
496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on First Allied Advisory Services's 13F filing for Q3 2020, filed 13 Nov 2020.